Tonix Pharmaceuticals, Inc.
26 Main Street – Suite 101
Chatham
New Jersey
07928
United States
Website: http://www.tonixpharma.com/
413 articles about Tonix Pharmaceuticals, Inc.
-
Tonix Pharma Announces Issuance Of U.S. Patent For Tnx-102 Sl Composition And Formulation: Designed For Transmucosal Absorption And Bedtime Daily Use
5/2/2017
-
Tonix Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Programs Update
4/17/2017
-
Tonix Pharma Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
4/14/2017
-
Tonix Pharma Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder
4/11/2017
-
Tonix Pharma Completes $8 Million Public Offering Of Common Stock
4/4/2017
-
Tonix Pharma Regains Compliance With NASDAQ Minimum Bid Price Requirement
4/3/2017
-
Tonix Pharma Prices Public Offering Of 1,800,000 Shares Of Common Stock
3/30/2017
-
Tonix Pharma Announces Proposed Public Offering Of Common Stock
3/30/2017
-
Tonix Pharma Enrolls First Participant In Military-Related PTSD Phase III Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL
3/28/2017
-
Tonix Pharma Announces 1-For-10 Reverse Stock Split
3/17/2017
-
Tonix Pharma Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL
3/14/2017
-
Tonix Pharma Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus
3/2/2017
-
Tonix Pharma Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference
1/11/2017
-
Tonix Pharma’s PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA
12/19/2016
-
Tonix Pharma Presented New Clinical Results From Sub-Group Analysis Of Phase II Atease Study In Military-Related Posttraumatic Stress Disorder (PTSD)
12/8/2016
-
Tonix Pharma Reports Third Quarter 2016 Financial Results
11/11/2016
-
Tonix Pharma To Present New Clinical Results From Retrospective Analysis Of Phase II AtEase Study In Military-Related PTSD
11/10/2016
-
Tonix Pharma Completes $5.2 Million Underwritten Public Offering
11/1/2016
-
Tonix Pharma Prices $5.2 Million Underwritten Public Offering
10/26/2016
-
Tonix Pharma Announces Proposed Underwritten Public Offering Of Common Stock And Warrants
10/26/2016